HLS Therapeutics Stock Price, News & Analysis (CVE:HLS) Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding HLS Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range N/A52-Week Range N/AVolume49,300 shsAverage Volume97,793 shsMarket CapitalizationC$384.86 millionP/E RatioN/ADividend Yield1.46%BetaN/A ProfileAnalyst RatingsEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. It is focused on treatment products for the central nervous system and cardiovascular specialties. The company was incorporated in 2014 and is headquartered in Toronto, Canada. Industry, Sector and Symbol Stock Exchange CVE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolCVE:HLS Previous Symbol CUSIPN/A CIKN/A Webhttp://www.hlstherapeutics.com/ Phone647-495-9000Debt Debt-to-Equity Ratio60.11 Current Ratio0.84 Quick Ratio0.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$65.13 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow38.84 Book ValueC$6.11 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares27,295,300Market CapC$384.86 million Next Earnings Date11/21/2019 (Estimated) OptionableNot Optionable Receive HLS News and Ratings via Email Sign-up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter. HLS Therapeutics (CVE:HLS) Frequently Asked Questions What is HLS Therapeutics' stock symbol? HLS Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HLS." How were HLS Therapeutics' earnings last quarter? HLS Therapeutics Inc (CVE:HLS) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.02. The business earned $18.23 million during the quarter, compared to analysts' expectations of $19.93 million. View HLS Therapeutics' Earnings History. When is HLS Therapeutics' next earnings date? HLS Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 21st 2019. View Earnings Estimates for HLS Therapeutics. What is the consensus analysts' recommendation for HLS Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for HLS Therapeutics. Has HLS Therapeutics been receiving favorable news coverage? Media headlines about HLS stock have trended very negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. HLS Therapeutics earned a news impact score of -3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for HLS Therapeutics. Who are some of HLS Therapeutics' key competitors? Some companies that are related to HLS Therapeutics include Hexo (HEXO), Knight Therapeutics (GUD), Ecofibre (EOF), OrganiGram (OGI), HEXO (HEXO), Next Science (NXS), Supreme Cannabis (FIRE), Green Organic Dutchman (TGOD), Benchmark (BMK), ICC Labs (ICC), Flowr (FLWR), Shield Therapeutics (STX), Amryt Pharma (AMYT), CannTrust (TRST) and Althea Group (AGH). What other stocks do shareholders of HLS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Allena Pharmaceuticals (ALNA), AcelRx Pharmaceuticals (ACRX), Ritter Pharmaceuticals (RTTR), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP), Ardelyx (ARDX) and ArQule (ARQL). Who are HLS Therapeutics' key executives? HLS Therapeutics' management team includes the folowing people: Mr. William M. Wells M.B.A., B.A., MBA, Co-Founder & Exec. Chairman (Age 57)Mr. Gregory David Gubitz L.L.B., B.A., LL.B, Co-Founder, CEO & Director (Age 61)Mr. Gilbert Godin, Pres & COO (Age 59)Mr. Tim Hendrickson M.B.A., Chief Financial Officer (Age 47)Mr. Joseph Anthony MacLean B. Com., LL.B, Director of Corp. Devel. (Age 50) How big of a company is HLS Therapeutics? HLS Therapeutics has a market capitalization of C$0.00 and generates C$65.13 million in revenue each year. View Additional Information About HLS Therapeutics. What is HLS Therapeutics' official website? The official website for HLS Therapeutics is http://www.hlstherapeutics.com/. How can I contact HLS Therapeutics? The company can be reached via phone at 647-495-9000. MarketBeat Community Rating for HLS Therapeutics (CVE HLS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 49 (Vote Outperform)Underperform Votes: 43 (Vote Underperform)Total Votes: 92MarketBeat's community ratings are surveys of what our community members think about HLS Therapeutics and other stocks. Vote "Outperform" if you believe HLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HLS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/17/2019 by MarketBeat.com StaffFeatured Article: Why do analysts give a neutral rating?